News
11-22-2019, 02:07 PM
The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast cancer, according to a large, randomized phase III study reported at the ESMO Asia 2019 Congress.
More... (https://www.news-medical.net/news/20191122/Biosimilar-for-HER22b-breast-cancer-achieves-similar-overall-response-rate-to-reference-drug.aspx)
More... (https://www.news-medical.net/news/20191122/Biosimilar-for-HER22b-breast-cancer-achieves-similar-overall-response-rate-to-reference-drug.aspx)